Outcome of allogeneic BMT for childhood ALL performed at a national centre was evaluated for the period between 1985 and 1996. Sixty-seven patients representing all Danish children and adolescents (1-19 years) transplanted for ALL, were evaluated. Patients transplanted with a family donor (n = 51) had a 3-year probability of leukaemia-free survival (P-LFS) of 56% (95% confidence limits 41-69%) and patients receiving marrow from a matched unrelated donor (MUD) (n = 16) had a 3-year P-LFS of 67% (34-86%) (P = 0.38). Relapse was responsible for 48% of the deaths and occurred with increasing frequency among children transplanted with marrow from HLA-identical siblings. Patients transplanted with family donors from 1985-1989 had P-LFS of 72% (54-84%) compared to patients transplanted after 1990 who revealed a significantly reduced P-LFS of 28% (10-49%, P = 0.01). Furthermore, the risk of relapse was increased (65% (24-88%)) (P = 0.02) in the later period. In contrast, patients transplanted with marrow from a MUD (1990-1996) had a lower risk of relapse (11%, 5-20%) (P = 0.002) but a comparable risk of transplant-related mortality. Children who experience relapse after modern, intensive treatment for ALL may have an increased propensity for relapse even after BMT. Therefore, when performing BMT for childhood ALL, there may be a benefit in overall survival from the increased graft-versusleukaemia effect that follows less intensive GVHD prophylaxis or transplantation with a MUD. Keywords: allogeneic bone marrow transplantation; acute lymphoblastic leukemia; children; unrelated donor
cause of treatment failure. In the Nordic countries, the prognosis after relapse has not improved, and only about 25-30% of children who relapse achieve a lasting second remission. 1 Bone marrow transplantation (BMT) has gained widespread acceptance as the treatment of choice for a variety of childhood diseases, particularly leukaemia resistant to conventional therapy. The major role for allogeneic BMT in childhood ALL is treatment of relapsing disease where BMT results in a better overall prognosis than chemotherapy alone. 5 Generally, transplantation using an HLA-identical family donor has been considered a safer option than using an alternative donor. However, only about 30% of patients have access to a matched family donor and recent progress in the availability of matched unrelated donors (MUD) has increased the number of such transplantations. [6] [7] [8] [9] In Table 1 Characteristics of patients transplanted with bone marrow from family donors 1985-1996
HLA-identical
Other family sibling members [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] 1985-1996 n = 29 n = 22 Denmark, transplants with marrow from MUDs have been performed for childhood ALL since 1990 and the frequency of such transplants has increased to nearly 50%. In this retrospective, population-based, one-institution study we examined the influence of donor type and prophylaxis against GVHD on the risk of relapse and overall survival in Danish children who underwent allogeneic BMT for high-risk ALL after 1984.
Patients and methods

Patients and donors
All Danish children and adolescents who underwent allogeneic BMT for ALL before the age of 20, were evaluated. Patients were transplanted at the national BMT Unit at Rigshospitalet, Copenhagen, which is the only centre for allogeneic BMT in Denmark. A total of 67 children and adolescents with ALL were transplanted between 1985 and 1996. The indications for BMT in childhood ALL have remained constant through this period. Most of the patients (67%) were in second complete remission (CR2) following early relapse within 6 months of termination of primary therapy. Sixteen percent of the patients were in CR1 but showed very high-risk characteristics such as T cell leukaemia with high leukocyte counts (Ͼ100 × 10 9 /l) or translocations such as t(9;22) or t(4;11). Sixteen percent of the patients were beyond CR2 at the time of transplantation. In all patients eligible for BMT, a matched sibling donor was used, if available. Patient characteristics are shown in Tables 1 and 2 .
Donors and recipients were matched at the A, B and DR loci by serology testing. In case of family donors other than HLA-identical siblings, and for unrelated donors, the DRB1 * genotype was determined using PCR and sequence-specific probes. DRB1 * genotypes were analyzed prospectively in all donor-recipient pairs after 1992 and retrospectively on frozen cells in pairs before 1992. Donors were either HLA-identical siblings (n = 29), 0-3 locus mismatched other family donors (n = 22), or unrelated donors (n = 16) with a maximum disparity of either one class I or one class II subtype mismatch. The distribution of remissions in the different donor type groups was almost the same.
Chemotherapy protocols prior to transplantation
Most of the Danish children with ALL were classified and treated according to common protocols prepared by the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia group. Relapsing patients were treated according to protocols prepared by the German Society of Pediatric Oncology and Hematology (GPOH).
Transplantation procedures
Pretransplant myeloablative conditioning in all patients consisted of either total body irradiation and cyclophosphamide (TBICY) (87%), or busulfan and cyclophosphamide (BUCY) (13%). TBI consisted of 12 Gy given in three fractions at 24-h intervals. Lungs were shielded to receive a total dose of 9 Gy, and boys received an additional 4 Gy of testicular irradiation. Busulfan was given p.o. at a total dose of 16 mg/kg body weight (in four daily doses for 4 days) and cyclophosphamide was given i.v. at a total dose of 120 mg/kg body weight on 2 separate days. In transplants with a donor other than an HLA-identical sibling, three doses (20 mg/kg each) of antithymocyte globulin (ATGAM; Pharmacia & Upjohn, Copenhagen, Denmark) were given prior to transplantation on 3 consecutive days.
GVHD The severity of acute GVHD was staged and graded according to standard criteria. 10 Chronic GVHD was defined and classified according to Shulman et al. 11 
Statistical methods
Probability of leukaemia-free survival (P-LFS) was defined as the probability of staying alive and being in continuous CR after BMT, and was calculated by the Kaplan-Meier product-limit method. Log-rank tests were used to test for differences in survival. The cumulative risk of relapse is presented by an inverted Kaplan-Meier curve in which the event was relapse. All P-LFS and risk of relapse are 3-year probabilities (95% confidence interval). Quantitative variables were compared using the Mann-Whitney test. The level of significance was 0.05 in all statistical tests. All analyses were performed using GraphPad Prism (ver 2.0).
Death in remission was defined as death due to any cause in patients who were in CR after BMT. Relapse was defined as histological evidence of recurrent leukaemia. Patient data and outcome were analysed as of 1 April 1997. The median duration of follow-up for the patient population was 41 months (range 2-148).
Results
A total of 67 patients were transplanted for ALL. Engraftment for the whole group was 97% and overall 3-year P-LFS was 59% (45-70%).
Outcome of ALL patients according to donor type
The 3-year P-LFS was 56% (41-69%) for children transplanted with a family donor (n = 51) and 67% (34-86%) for MUD transplants (n = 16) (P = 0.38). Likewise, no difference in 3-year P-LFS was observed when comparing patients transplanted with an HLA-identical sibling graft (P-LFS = 55% (36-71%)) to a graft from other family members (P-LFS = 58% (36-75%)) ( Table 1) .
Outcome of ALL patients transplanted with family donors only
Comparison of patients transplanted with family donors before and after 1990, which was the year MUD transplantation for childhood ALL was started in Denmark, revealed a reduced P-LFS (28% (10-49%)) for the period 1990-1996, as compared to the period 1985-1989 (72% (54-84%)) (P = 0.01) (Figure 1a) . The risk of relapse was significantly increased to 65% (24-88%) (P = 0.02) in the later time period, explaining the difference in P-LFS between the two periods (Figure 1b) . The distribution between HLAidentical sibling donors and other family donors did not differ between the two time periods (18/14 (1985-1989) and 11/8 (1990-1996) ) ( Table 2) .
Outcome according to GVHD prophylaxis in patients transplanted with HLA-identical siblings
Before 1992 GVHD prophylaxis consisted of CsA only. However, from 1992 GVHD prophylaxis with three or four doses of MTX was included for recipients of HLA-identical sibling marrow. With this exception, transplantation procedures were unchanged during the study period. Figure 2a depicts the difference in P-LFS in patients stratified according to the two regimens of GVHD prophylaxis. Patients receiving both CsA and MTX had a very low P-LFS approaching zero (P = 0.0005). Figure 2b shows that the low P-LFS is explained by a high risk of relapse in this group receiving both CsA and MTX as GVHD prophylaxis.
Outcome in patients transplanted with a MUD
The P-LFS for patients transplanted with a MUD (n = 16) was 67% (34-86%), and in this group only one patient has relapsed. Furthermore, when the MUD group was compared to patients (n = 13) transplanted during the same period (1990) (1991) (1992) (1993) (1994) (1995) (1996) receiving family donor allografts and the same GVHD prophylaxis (CsA and MTX) (Figure 3a , b and c) the difference in P-LFS was found to be pronounced (P = 0.002). Patients receiving grafts from family donors had a P-LFS of 18% (4-39%), and a high risk of relapse (76% (13-96%) ). The procedure-related mortality did not differ between the two groups ( Figure 3c ). With respect to clinical risk factors, the two groups were comparable except for a higher proportion of girls (P Ͻ 0.01), a higher proportion of children above 10 years of age at onset of ALL Table 2) .
Causes of death
Twenty-nine of 67 patients (43%) have died. Marrow relapse was the most frequent cause of death after BMT, and was responsible for 48% of the deaths. Two patients with a relapse following BMT are still alive and in remission 14 months and 9 years after relapse. Relapse was not associated with a higher initial white blood cell count, or a first remission below 18 months. Among 29 patients transplanted with an HLA-identical sibling 13 died, and 10 (77%) of these died from relapse. GVHD was the second most common cause of death, responsible for 25% of the deaths.
Discussion
Among this group of children and adolescents with high risk ALL, the 3-year P-LFS after BMT was 59% (45-70%) for the whole group, and 56% (41-69%) among patients transplanted with family donors. This result is comparable to other studies.
12 Surprisingly, when stratifying for time, we found an alarmingly and significantly reduced survival (P-LFS of 28% (10-49%)) among patients transplanted with family donors from 1990 to 1996. Furthermore, the risk of relapse was significantly increased (65% (24-88%)) for this group of patients.
As an explanation for this recent increase in the risk of relapse for patients receiving an HLA-identical sibling graft, we propose the following: (1) Pre-transplant treatment may play a decisive role in the increase in relapse rate after BMT. As chemotherapy for ALL becomes more and more intensive, more children remain in first remission, and the selected group of patients who relapse after intensive treatment may have a more aggressive disease with a poorer prognosis even after BMT. (2) The change in GVHD prophylaxis from monotherapy with CsA to the combination of CsA and MTX may also play a role. The combination of CsA and a short course of MTX is widely used as the immunosuppressive regimen for preventing GVHD. However, all our patients receiving a graft from an HLA-identical sibling who received this combination of GVHD prophylaxis have relapsed within 1. years post-BMT. Another study in leukaemic patients transplanted with marrow from HLA-identical siblings has shown a similarly increased risk of relapse if GVHD prophylaxis consisted of both CsA + MTX instead of CsA or MTX alone. 13 In contrast to transplants with family donors, we found a better survival for children transplanted with MUDs, superior to most other studies evaluating unrelated transplantation in children. 6, 8, [14] [15] [16] [17] [18] To compare patients transplanted with MUDs to patients transplanted with family donors, we stratified for time and GVHD prophylaxis in an attempt to make the groups similar. Patients receiving MUD BMTs did not differ significantly from patients transplanted with family donors with respect to clinical risk factors, except for the higher proportion of girls and children beyond 10 years of age, and a longer interval from last remission to time of transplant. Among the two groups of patients, MUD transplants had a lower risk of relapse and a much more favourable outcome than transplantations with family donors. This is most likely caused by the increased graft-versus-leukemia (GVL) effect which is the consequence of MUD BMT. A low incidence of relapse among MUD BMTs has also been observed in other studies, 18 but is often complicated by a high early death rate in recipients of MUD grafts, resulting in fewer MUD graft recipients at risk of relapse over time, and in the end not resulting in an improved overall survival. 15, 19 The prolonged interval from remission to time of transplant with a MUD is explained by the extra time needed for the donor search in international registers. The proportion of patients in whom a transplant was considered but who did not survive the waiting time is not known. Although procedure-related mortality was low in MUD BMT, the incidence of GVHD is high; in particular, chronic GVHD was more frequent in the MUD group (P Ͻ 0.05) ( Table 2 ). In addition donor age was, as expected, higher in the MUD group than among sibling donors (data not shown), which could be a contributing factor for the development of GVHD.
The safety of transplantation with an unrelated donor graft without T cell depletion has been limited by morbidity and mortality from GVHD and opportunistic infections, 19 although better survival in children than adults is often observed. 15, 20 Depleting of donor T cells from the graft of an unrelated donor is an effective method of reducing the incidence and severity of acute and chronic GVHD. 7, 8 However, this procedure may be associated with an increased risk of graft rejection and relapse as compared to transplantation with a non-T cell-depleted MUD graft. In our study, the procedure-related mortality was not increased compared to that found for patients transplanted with HLA-identical sibling donors.
The validity of the conclusions drawn from our study may be hampered by the relatively small number of patients. Conclusions, however, are strengthened by the fact that this is a population based, one-centre study dealing with a homogenous patient group. Relapse after allogeneic BMT seems to be an increasing problem in transplantation with HLA-identical sibling donors for childhood ALL. Children who experience relapse after modern, intensive treatment for ALL may have an increased propensity for relapse after BMT. In our hands, transplantation with MUDs results in better survival due to a lower risk of relapse compared to patients transplanted with family donors. Therefore, in BMT for ALL, children and adolescents may benefit from the increased GVL effect following either less intensive GVHD prophylaxis or MUD BMT.
